Eltrombopag
As of the edition of 20 October 2026, Eltrombopag is a small molecule: marketed, first approved in 2008 (US); acts on MPL; US protection ended in 2025.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Promacta
- First approved
- 20 November 2008 (US)
- Approvals on record
- 18 in 4 regions
- Holder of the most recent approval
- Teva; 4 holders in all
- Registered trials
- 155, 19 stopped early
- Disease areas
- Blood and lymph; Immune system; Cancer; Digestive system; Infections; Inherited and neonatal
US protection
US protection ended in 2025.
The last listed US drug-substance patent ended in 2025.
Teva holds a later exclusivity on its own new formulation or combination product, ending 2038; it does not protect the original drug.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product29 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 29 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Eltrombopag.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MPL | Thrombopoietin receptor | P40238 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 21 | 11 | 6 | 1 |
| Phase 1 | 18 | 13 | 0 | 3 |
| Phase 2 | 80 | 43 | 16 | 12 |
| Phase 3 | 27 | 18 | 3 | 2 |
| Phase 4 | 9 | 3 | 3 | 1 |
| All trials | 155 |